Get all your news in one place.

100's of premium titles.
One app.

Start reading

Get all your news in one place.

100's of premium titles. One news app.

Start reading

The Latest Breaking News from Novartis

CEO says she’d welcome an AI-bot board member: ‘If you don’t have an AI agent in every meeting, you’re missing out’

Hanneke Faber speaks about the value of AI in decision-making at the Fortune Most Powerful Women Summit.

Fortune

Should You Buy Novartis Stock Before October 28?

Novartis is gaining traction this year, but can the trend continue?

Barchart

How high-cost Switzerland stayed a manufacturing powerhouse in the offshore era

What is the lesson of Swiss Fortune 500 companies—such as dsm-firmenich—for the rest of Europe, and the world?

Fortune

From analysis to the latest developments in health,
read the most diverse news in one place.

Pharma's Direct-To-Patient Wave Hits Novartis Next

The Pharmaceutical Research and Manufacturers of America (PhRMA) outlined initiatives to bolster U.S. manufacturing, ease patient costs, and improve access to medicine.

Benzinga

The Nations And Firms Threatened By Trump's Pharma Tariffs

Donald Trump has shocked the global drug industry by announcing 100-percent tariffs on all branded, imported pharmaceutical products -- unless companies are building manufacturing plants in the United States.

International Business Times

Trump’s latest tariff threat raises concerns for UK pharmaceuticals

Britain will ‘actively engage’ with US over possible 100% duties, with truck and cabinet makers also in firing line

The Guardian - UK

Novartis, AbbVie Face Legal Defeat Over 340B Contract Pharmacies

A U.S. federal judge has rejected challenges by two pharmaceutical manufacturers seeking to block a Maine law that regulates the use of contract pharmacies under the federal 340B drug discount program.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Novartis Builds US Drug Reserves Against Potential Tariffs

Novartis AG (NYSE:NVS) has reportedly built up its pharmaceutical stockpiles in the U.S. as a cushion against the potential impact of tariffs under consideration by the Trump administration, chief executive Vas Narasimhan said in a recent interview.

Benzinga

Novartis Chief Eyes Ways To End Higher US Drug Prices: Media

Amid a threat of towering US tariffs, Swiss pharmaceutical giant Novartis is seeking ways to enable Americans to pay less for their medicines, its chief said in an interview published Saturday.

International Business Times

Big pharma firms have paused nearly £2bn in UK investments this year

Government’s plans in disarray before Trump talks as MSD, Eli Lilly and AstraZeneca moves prompt job fears

The Guardian - UK

Monte Rosa, Novartis Use AI-Powered Engine To Advance Immune Disease Treatments

Monte Rosa Therapeutics Inc. (NASDAQ:GLUE) stock is surging on Monday, with a session volume of 11.67 million compared to the average volume of 408.08 thousand as per data from Benzinga Pro.

Benzinga

Trump's Biotech Playbook Ignites $350 Billion Investment Blitz

Biotech is back – and it's playing for keeps. President Donald Trump's second-term policies have unleashed a staggering ~$350 billion surge in U.S.-based pharmaceutical and biotech investments, from domestic manufacturing to cutting-edge RD. For investors, it's a rare opportunity: major drugmakers are expanding fast, and some could be poised to…

Benzinga

Tourmaline Bio, QMMM Holdings, Teck Resources And Other Big Stocks Moving Higher On Tuesday

U.S. stocks were lower, with the Nasdaq Composite falling around 0.1% on Tuesday.

Benzinga

Novartis' Moonshot Cancer Therapy Could Be Future Growth Driver

Novartis is betting big on radioligand cancer therapy, but while the long-term growth story looks strong, NVS stock may face a short-term pullback

MarketBeat

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Novartis To Expand Heart Drug Portfolio With $1.4 Billion Tourmaline Bio Acquisition

Tourmaline Bio, Inc. (NASDAQ:TRML) shares surged Tuesday after Novartis AG (NYSE:NVS) announced a $1.4 billion acquisition of the U.S.-based biotech, strengthening the Swiss drugmaker’s pipeline of cardiovascular and kidney treatments.

The National (Scotland)

Scotland becomes first in UK to screen babies for 'devastating' rare condition

Scotland is to become the first part of the UK to routinely screen newborn babies for a 'devastating' rare medical condition ...

Evening Standard

Scotland first part of the UK to screen babies for ‘devastating’ rare condition

From early 2026 it is expected babies born in Scotland will be routinely tested for Spinal Muscular Atrophy.

The Independent UK

Groundbreaking cholesterol jab could revolutionise heart disease care

Leqvio saw users achieve their target cholesterol levels faster than existing treatments

Get all your
news in one place.

100's of premium titles.
One news app.

Evening Standard

Jab for high cholesterol could ‘transform’ heart care

Cholesterol is a fatty substance made by the liver and found in some foods.

Benzinga

Novartis Sees Hope In Reducing Lifelong Treatment Burden For Autoimmune Blood Disorder

Novartis AG (NYSE:NVS) released topline results on Tuesday from the VAYHIT2 Phase 3 trial evaluating ianalumab plus eltrombopag in patients with primary immune thrombocytopenia (ITP) previously treated with corticosteroids.

Benzinga

Novartis' Investigational Drug Aces Two Pivotal Trials For Chronic Disease Impacting Tears, Saliva

Novartis AG (NYSE:NVS) on Monday released topline data from two Phase 3 trials, NEPTUNUS-1 and NEPTUNUS-2, evaluating ianalumab (VAY736) in adults with active Sjögren’s disease.

The Independent UK

The Latest: US trade partners around the world react to Trump's new tariffs

U.S. trade partners are reacting to President Donald Trump’s executive order that would introduce new tariffs on many of them in seven days

The Conversation

First malaria treatment for babies is a major step to ending the disease in Africa - biochemist

The first malaria treatment for babies and very young children of 2 months up to 5 years was approved for use by Swiss agency for therapeutic products, Swissmedic, in early July 2025. Until now, babies and very young children have been treated with medicines formulated for older children.

Benzinga

Novartis Raises Operating Income Outlook After Strong Q2 Performance, Initiates $10 Billion Stock Buyback (CORRECTED)

Editor’s Note: The title of the story has been corrected to reflect that the outlook was raised, instead of the erroneous “outlook cut” mentioned in the original title.

The Independent UK

Hope for developing world as Swiss anti-malarial for newborns approved

IN FULL

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.